Compass Pathways (CMPS) gained by $3.66 or 10.41% yesterday to close at $38.82 per share for its second biggest up day since its IPO less than one month ago (excluding its first day of trading). CMPS is up another $0.41 or 1.06% this morning to $39.23 per share. CMPS is currently conducting a 216 patient randomised controlled Phase 2b trial of psilocybin therapy for treatment-resistant depression in 20 sites across Europe and North America.
Our #1 favorite small-cap psilocybin play Numinus Wellness (TSXV: NUMI) hit another new 3-month high yesterday of $0.385 per share on strong volume of 2,248,625 shares. NUMI has gained on the last four straight trading days.
Past performance is not an indicator of future returns. Psychstocks is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. This message is not a solicitation or recommendation to buy, sell, or hold securities. The parent company of Psychstocks has been compensated by NUMI USD$30,000 cash for a six-month marketing contract. This message is meant for informational and educational purposes only and does not provide investment advice.